GLOBAL HEALTH LTD - Symmetrical Triangle BreakoutThis is still an open candle and need to wait till this candle closes in GREEN on Friday end of the day. If the candle is green and is clearly breaking out from the triangle on Friday, it is a Bullish sign.
On the daily time frame, the daily candle has closed in GREEN, which is a good sign.
The Risological indicators confirm the bullish movement as seen below.
ENTRY:
The stock can be purchased on the daily time frame as the Risological indicators gave the confirmation
EXIT:
Hold the BUY position till the Risological indicator gives a reversal
Exit on first RED candle close on the daily time frame.
OR, Exit if the Risological options trading indicator turns into RED.
Hope this helps!
Cheers!
__All info = educational only__
Globalhealth
Can Market Turbulence Create Future Innovation?In a dramatic turn of events that sent shockwaves through the pharmaceutical industry, Novo Nordisk's recent setback with its experimental obesity drug CagriSema presents a fascinating case study in market resilience and scientific progress. The company's stock plummeted 24% after trial results showed a 22.7% weight reduction efficacy, falling short of the anticipated 25% target. Yet, beneath this apparent disappointment lies a deeper story of pharmaceutical innovation and market adaptation.
The obesity treatment landscape stands at a pivotal crossroads, with the market experiencing exponential growth from its modest beginnings to a staggering $24 billion industry in 2023. Novo Nordisk's journey, alongside competitor Eli Lilly, exemplifies how setbacks often catalyze breakthrough innovations. The CagriSema trial, involving 3,400 participants, represents a clinical study and a testament to the industry's commitment to addressing global health challenges.
Looking ahead, this moment of market recalibration might well be remembered as a turning point in the evolution of obesity treatment. With projections suggesting a potential $200 billion market by the early 2030s, the current turbulence could drive even greater innovation and competition. The fact that only 57% of trial participants reached the highest CagriSema dose points to untapped potential and future opportunities for optimization, suggesting that today's apparent setback might pave the way for tomorrow's breakthroughs.